

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

SYS6036 INJECTION OBTAINS CLINICAL TRIAL APPROVAL IN CHINA

The Board of Directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that SYS6036 Injection (the “**Product**”) developed by the Group has obtained approval from the National Medical Products Administration of the People’s Republic of China to conduct clinical trials in China.

The Product, a humanized monoclonal antibody drug for cancer immunotherapy, has been applied for as a Class 3.3 therapeutic biological product and is expected to be indicated for the treatment of multiple cancer types such as melanoma, non-small cell lung cancer, esophageal cancer, and head and neck squamous cell carcinoma.

The Product was developed in accordance with the relevant research guidelines for biosimilars. Results from pharmaceutical and non-clinical studies demonstrated that the Product was highly similar to the reference drug in terms of quality, safety and efficacy, supporting the initiation of subsequent clinical studies.

By Order of the Board
CSPC Pharmaceutical Group Limited
CAI Dong Chen
Chairman

Hong Kong, 22 August 2025

As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin and Mr. CHEN Weiping as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as independent non-executive directors.